CXCL10 and neoplasm: Consistently, LLC and MC38 tumor-infiltrating CD11c+ MHCII+ CD11b+ Ly6c+ CXCL10+ DCs were significantly increased in CD45+ cells in the RORγt agonist-treated group compared with the vehicle group, and CCL20 levels were higher in RORγt agonist-treated tumor tissue compared to vehicle treated tumors (Fig. 6a).